SCHEMBL332668

SCHEMBL332668

Cn1ncc2ccccc2c1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 8/20 0.51
RAB9A P51151 8/20 0.51
SMN1; SMN2 Q16637 5/20 0.51
ALDH1A1 P00352 3/20 0.51
LMNA P02545 3/20 0.51
KMT2A Q03164 2/20 0.51
MEN1 O00255 1/20 0.51
GLA P06280 1/20 0.51
NFKB1 P19838 1/20 0.51
NFKB2 Q00653 1/20 0.51
RELA Q04206 1/20 0.51
POLB P06746 1/20 0.51
MITF O75030 1/20 0.50
PKM P14618 1/20 0.50
KDM4E B2RXH2 2/20 0.49
PLA2G10 O15496 1/20 0.47
TP53 P04637 1/20 0.46
HSD17B10 Q99714 1/20 0.46
PAX8 Q06710 1/20 0.46
CA12 O43570 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29509350 1.00 NPC1 (0.51) NPC1RAB9ASMN1; SMN2ALDH1A1LMNA
Hydrochloric Acid SCHEMBL30088901 0.98 NPC1 (0.50) NPC1RAB9ASMN1; SMN2ALDH1A1LMNA
SCHEMBL7889097 0.80 NPC1 (0.51) NPC1RAB9ASMN1; SMN2ALDH1A1LMNA
SCHEMBL16013953 0.78 CHEK1 (0.44) NPC1RAB9ASMN1; SMN2ALDH1A1POLB
SCHEMBL19152811 0.77 KAT2B (0.39) SMN1; SMN2ALDH1A1BRD4BPTFKAT2B
SCHEMBL19153953 0.77 KDM4C (0.41) ALDH1A1LMNAKDM4EMAPK1HTT
SCHEMBL10044417 0.77 NPC1 (0.62) NPC1RAB9ASMN1; SMN2ALDH1A1LMNA
SCHEMBL5166784 0.76 NPC1 (0.56) NPC1RAB9ASMN1; SMN2ALDH1A1LMNA
SCHEMBL14125604 0.76 NPC1 (0.51) NPC1RAB9ASMN1; SMN2ALDH1A1LMNA
SCHEMBL7764110 0.76 NPC1 (0.51) NPC1RAB9ASMN1; SMN2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210147364-A1 A CATALYST BOUND ALPHA RADICAL AND SYNTHESIS OF OXO COMPOUNDS USING THE SAME COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2021-05-20 US claimed
EP-1878717-A1 Benzyl amines, a process for their production and their use as anti-inflammatory agents Bayer Schering Pharma Aktiengesellschaft (DE) 2008-01-16 EP claimed
US-4096143-A Process for producing phthalazinone and derivatives of the same FUJI PHOTO FILM CO., LTD. (JA) 1978-06-20 US claimed
US-20250340519-A1 RADIOLABELLED COMPOUND OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2025-11-06 US disclosed
EP-4624459-A2 RADIOLABELLED COMPOUND Oxford University Innovation Limited (GB) 2025-10-01 EP disclosed
WO-2025020886-A1 AZAQUINAZOLINE RING DERIVATIVE AND USE THEREOF 浙江星浩澎博医药有限公司 2025-01-30 WO disclosed
WO-2024182693-A1 2-AZASPIRO[3.3]HEPTANE DERIVATIVES AS STAT3 INHIBITORS FOR THE TREATMENT OF CANCER VIVIDION THERAPEUTICS, INC. (US) 2024-09-06 WO disclosed
CN-114560814-B Synthesis method of substituted 2, 3-naphthyridine ketone compound 天津理工大学 2023-10-20 CN disclosed
US-20230312481-A1 SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF ARBUTUS BIOPHARMA CORP (CA) 2023-10-05 US disclosed
WO-2023088425-A1 15-PGDH INHIBITOR AND USE THEREOF 武汉人福创新药物研发中心有限公司 2023-05-25 WO disclosed
US-20220403383-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2022-12-22 US disclosed
US-20050209324-A1 Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2005-09-22 US disclosed
US-20050171109-A1 Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2005-08-04 US disclosed
WO-2005034939-A1 1-AMINO-2-OXY-SUBSTITUTED TETRAHYDRONAPHTALENE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF, AND THEIR USE AS ANTIPHLOGISTICS SCHERING AKTIENGESELLSCHAFT (DE) 2005-04-21 WO disclosed
EP-0164593-B1 ANTI-INFLAMMATORY PHTHALAZINONES FISONS CORPORATION (US) 1989-11-15 EP disclosed
US-4665181-A Anti-inflammatory phthalazinones PENNWALT CORPORATION (US) 1987-05-12 US disclosed
EP-0164593-A1 Anti-inflammatory phthalazinones FISONS CORPORATION (US) 1985-12-18 EP disclosed
US-4258129-A IMPROVE GREEN SHELF LIFE FUJI PHOTO FILM CO., LTD. (JP) 1981-03-24 US disclosed
US-4211839-A SILVER HALIDE AND ORGANIC SILVER SALT PREPARED IN AN IMINO COMPOUND FUJI PHOTO FILM CO., LTD. (JP) 1980-07-08 US disclosed
US-4096143-A Process for producing phthalazinone and derivatives of the same FUJI PHOTO FILM CO., LTD. (JA) 1978-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250340519-A1 RADIOLABELLED COMPOUND PARP3, PARP2, PARP1 NPC1 2451/4885RAB9A 1654/4885SMN1; SMN2 4502/4885
US-20220403383-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SNRPA1 NPC1 2258/4885RAB9A 3071/4885SMN1; SMN2 123/4885
US-20050171109-A1 Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents TNF, DHPS, PTGES NPC1 1696/4885RAB9A 2917/4885SMN1; SMN2 4513/4885
US-20210147364-A1 A CATALYST BOUND ALPHA RADICAL AND SYNTHESIS OF OXO COMPOUNDS USING THE SAME CBR1, POR, CAT NPC1 2584/4885RAB9A 1529/4885SMN1; SMN2 3956/4885
US-20230312481-A1 SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF NSD3, PML, NSD1 NPC1 910/4885RAB9A 2543/4885SMN1; SMN2 3828/4885
US-20050209324-A1 Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents TNF, DHPS, PTGES NPC1 1696/4885RAB9A 2917/4885SMN1; SMN2 4513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.